
    
      This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of
      cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites
      in the United States. Study subjects will be divided evenly across a low dose, a medium dose
      group, a high dose and placebo group for one treatment cycle.
    
  